A phase II trial of a non-myeloablative regimen combining in vivo T cell depletion with an anti-CD52 monoclonal antibody (alemtuzumab), and chemotherapy with fludarabine and melphalan prior to a related or unrelated hematopoietic stem cell transplantation  by Castro-Malaspina, H. et al.
Between 05/98 and 07/03, twelve consecutive patients with FA
received hematopoietic stem cell transplants at our center. There
were 6 males and 6 females aged 5 to 24 years (median 12.8).
Hematologic diagnoses included aplastic anemia (N  4), myelo-
dysplastic syndrome (MDS) in RA (N  1), RAEB (N  4),
RAEBT (N  1) or acute myelogenous leukemia (N  2). Nine
patients were heavily transfused and ten patients had received
treatment with oxymetholone prior to SCT. Eight patients were in
complementation group FA-A and four in group FA-G.
Six patients had related mismatched donors transplants with
respective matching at 4/6 (7/10), 4/6 (8/10), 5/6 (8/10) (3 pts) and
5/6 (9/10) HLA-antigens. Six patients had unrelated donors trans-
plants with respective matching at 5/6 (7/10), 5/6 (8/10), 5/6
(8/10), 5/6 (9/10) and 6/6 (10/10) (2 pts) HLA-antigens.
Cytoreduction included single dose total body irradiation (TBI)
(450 cGy), ﬂudarabine (30 mg/m2 x 5) and cyclophosphamide (10
mg/Kg x 4). Immunosuppression included anti-thymocyte globulin
and FK506 for all patients. The ﬁrst four patients also received
steroids peri-transplant. Grafts were G-CSF mobilized CD34
and E-rosette negative (E-) peripheral blood stem cell transplants
for 9 patients and soybean agglutinin negative (SBA-) and E-mar-
row transplants for 3 patients. Cell doses of the grafts were 1.5-
29.6 x 106 CD34 cells/Kg and 0-26 x 103 CD3 cells/Kg.
All patients engrafted. Possible Graft-versus-host disease of the
gut occurred in one patient and resolved completely prior to
treatment. With a median follow-up of 2.5 years (range 0.3-5), 10
of 12 patients are alive and 9 of 12 are alive disease-free. Two
patients died of: sepsis/ARDS (N  1) 2 months post SCT and
pneumonitis/ARDS and EBV-infection 6 months post SCT. One
patient relapsed 8 months post transplant, received a secondary
transplant from the same donor following busulfan and Cy and is
alive, disease-free 12 months post transplant. Six of the 7 evaluable
patients developed normal T-cell numbers and function at 6-8
months post SCT. All evaluable patients are fully engrafted with
stem cells originating from their donor. In summary, we report
successful T-cell depleted stem cell transplants from alternative
donors for the treatment of Fanconi anemia, using a ﬂudarabine
based cytoreduction. All patients experienced rapid hematopoietic
engraftment, early immune reconstitution and no or minimal
GVHD.
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Castro-Malaspina, H., Papadopoulos, E., Ann, J., Miguel Angel, P.,
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We report the results of a study designed to evaluate the safety
and efﬁcacy of hematopoietic stem cell transplants from HLA (A,
B, DRB1) matched or single HLA allele disparate related or un-
related donors after non-myeloablative cytoreduction with alemtu-
zumab (Campath-1H), 80 mg, ﬂudarabine, 125 mg/m2, and mel-
phalan, 100-140 mg/m2, and GvHD prophylaxis with cyclosporine
alone. Thirty-six patients received transplants for CLL/WD/MM
(4), NHL (14), HD (11), MDS, refractory anemia subtype (2),
AML in CR (4) or Ph’ve ALL or CR (1). All patients were
ineligible for myeloablative transplants because of a prior SCT
(16), refractoriness to prior chemotherapy and/or radiation (11),
age 60 (6) or other comorbidities. Donors included 16 HLA
matched and 2 HLA disparate siblings, and 18 HLA matched (13)
or HLA disparate (5) unrelated donors. Thirty-three patients re-
ceived G-CSF mobilized PBSC and 3 patients received bone mar-
row. The preparative regimen was relatively well tolerated, 8 pa-
tients had grade 3 oral mucositis and 2 heavily pretreated patients
had grade 4 pulmonary toxicity. Engraftment occurred in all 35
evaluable patients (one early toxic death). Only 7 patients devel-
oped acute GvHD, 4 of them had grade III/IV. The cumulative
incidence of GvHD was 23%. Four patients developed chronic
GvHD. With a median followup of 8 months (range 1 to 24
months), 26 patients survive and 10 have expired (5 due to disease
progression, 3 to infection, and 2 to regimen-related toxicity). The
overall survival (OS) for all patients was 63%. For recipients of
HLA matched related transplants the OS was 67% and 60% for
recipients of mismatched related and unrelated transplants, respec-
tively. The progression-free survival (PFS) for all patients was
54%, 57% for recipients of HLA matched related transplants and
53% for recipients of mismatched related and unrelated trans-
plants. The cumulative incidence of transplant (non-relapse) re-
lated mortality at two years was 18%. This study demonstrates that
this non-myeloablative preparative regimen is associated with du-
rable engraftment, reduced toxicity, and low incidence of acute and
chronic GvHD. These results are encouraging. Longer followup
will be required to ascertain the long-term DFS.
93
MYELOABLATIVE RELATED-DONOR ALLOGENEIC STEM CELL TRANS-
PLANTS (ALLOMSCT) ARE FEASIBLE AND CAN BE PERFORMED SAFELY
IN THE TOTALLY OUTPATIENT AMBULATORY SETTING
Mandanas, R.A.1, Geister, B.V.2, Underwood, B.J.3 1. Western Okla-
homa Blood and Marrow Transplant Program, Cancer Care Associates,
Oklahoma City, OK.
Autologous myeloablative stem cell transplants are now widely
performed in the outpatient environment due to advances in sup-
portive care. Similar advances can be applied to the allogeneic
myeloablative transplant (AlloMSCT) situation to potentially ob-
viate hospitalization. Since 1999, patient candidates for AlloMSCT
were evaluated noting for availability of a 24-hour caregiver, per-
formance status of 0-1, sufﬁcient understanding of the transplant
procedure, residence within a 50-mile radius or provision of hous-
ing near the facility. Dedicated home health care nurses were
available for off-ofﬁce hours and weekend calls to provide home
infusion of intravenous medications and blood products. Protocols
for the outpatient management of febrile neutropenia were insti-
tuted and criteria for hospitalization included signs of early shock,
severe mucositis, diarrhea, bleeding, Gr 3-4 graft-versus-host dis-
ease (GVHD), and other unexpected events deemed by the trans-
plant physician to require hospitalization. Twelve patients (6 AML,
4 NHL, 1 CML, 1 CLL) received sibling AlloMSCT (6/6 antigen-
match  11, 5/6 antigen-match  1) over a 4 year period. Median
age was 48 years (range 30-59) with 7 males and 5 females. Donors
were mobilized using G-CSF 10 g/kg x 4-5 days before leuka-
pheresis of a target CD34 cell count of 4.0 x 106/kg recipient
weight. Preparative regimens included Cyclophosphamide (CY)
120 mg/kg  Total Body Irradiation 12Gy in 6 patients, oral
Busulfan 16 mg/kg  CY 120 mg/kg in 3 patients and
BCNUEtoposideCytarabineCY (BEAC) in 3 patients. Six
required hospitalization (average 9.6 days, range 3-19) due to acute
Gr 3-4 GVHD (3), severe mucositis (2), or sepsis syndrome (1).
The other six patients were managed totally in the outpatient
setting during the ﬁrst 100 days. Early deaths (30 days) occurred
in 2 refractory NHL patients: 1 with rapid CNS relapse and
another with hepatic venoocclussive disease. Two other patients
died of complications of GVHD: 1 AML with hepatic failure plus
mucormycosis and 1 AML with severe pulmonary GVHD 2.5 and
18 mons post-transplant respectively. Eight patients are alive in
complete remission from 1-4.5 years post-transplant. Acute
GVHD occurred in 6/10 evaluable patients but only 3/10 patients
remain to date without evidence of some form of chronic GVHD.
Thus, AlloMSCT can be feasibly performed on an outpatient basis
with proper supportive care measures and immediate provision of
hospitalization only if necessary.
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